For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

Abbvie's commitment to
exceptional
access and patient
support

Get started with the
Enrollment & Prescription Form

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

RINVOQ is for moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

EXCEPTIONAL COMMERCIAL COVERAGE
FOR RINVOQ (upadacitinib)1,2,*,†

Preferred coverage means a product is placed on the plan’s preferred formulary. Preferred may include the lowest copay or coinsurance tier

RINVOQ has 99% preferred commercial coverage RINVOQ has 99% preferred commercial coverage RINVOQ has 99% preferred commercial coverage

Preferred coverage also could mean a STANDARD PRIOR AUTHORIZATION (PA) and APPEALS PROCESS, potential for one-time PA/appeal approval.

*Formulary definitions: Preferred means RINVOQ is placed on the plan's preferred formulary.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor; JAKi=Janus kinase inhibitor; TIM=targeted immunomodulator

Preferred coverage also could mean a
STANDARD PRIOR AUTHORIZATION (PA)
and APPEALS PROCESS, potential for one-time PA/appeal approval.

Commercial plan preferred formulary status for 2L TIM therapies for moderate to severe RA under the pharmacy benefit in 20222

National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit

Cimzia, Actemra, and Orencia are available as products on medical benefits plans.3-5

Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.

Products listed here are not interchangeable and not all products are shown. Material differences exist between products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.

No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.

*Formulary definitions: Preferred means RINVOQ is placed on the plan's preferred formulary.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor; JAKi=Janus kinase inhibitor; TIM=targeted immunomodulator

Please see HUMIRA full Prescribing Information.

Look up commercial insurance plans for RINVOQ in your area:

    EXCEPTIONAL MEDICARE
    PART D COVERAGE FOR RINVOQ (upadacitinib)1,2,*,†

    Medicare Part D preferred coverage - RINVOQ has achieved 95% Medicare Part D coverage Medicare Part D preferred coverage - RINVOQ has achieved 95% Medicare Part D coverage Medicare Part D preferred coverage - RINVOQ has achieved 95% Medicare Part D coverage

    Payers cover RINVOQ after the trial of 1 TNFi, with 95% of patients having Medicare Part D preferred coverage.*

    *Preferred coverage means a product is placed on the plan's preferred formulary. Preferred may include the lowest copay or coinsurance tier.

    Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

    Payers cover RINVOQ after the trial of 1 TNFi,
    with 95% of patients having Medicare
    Part D preferred coverage.*

    Medicare Part D plan preferred formulary status for 2L TIM therapies for moderate to severe RA under the pharmacy benefit in 20222

    National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit National commercial plan formulary status under the pharmacy benefit

    Cimzia, Actemra, and Orencia are available as products on medical benefits plans.3-5

    Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.

    Products listed here are not interchangeable and not all products are shown. Material differences exist between products, including with respect to safety profiles and line of therapy. Consult each individual product's USPI for full details.

    No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.

    *Preferred coverage means a product is placed on the plan's preferred formulary. Preferred may include the lowest copay or coinsurance tier.

    Please see HUMIRA full Prescribing Information.

    Two products.
    One exceptional patient experience.

    RINVOQ® COMPLETE
    HUMIRA® COMPLETE

    NURSE
    AMBASSADORS*

    Empower patients

    Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete

    Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:

    • Help patients understand the importance of following the treatment plan prescribed by their healthcare professional.
    • Committed to answering questions throughout the experience to help limit treatment disruptions.
    • Answer patients’ insurance questions and connect them with additional insurance expertise.
    • Identify ways for patients to save on prescription costs.

    ACCESS
    SPECIALISTS

    Insurance support when needed

    • Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
    • Can educate on payer prior authorization and appeal processes so you can determine the best access option for each patient’s unique situation.

    ACCESS & SAVINGS

    Help with access &
    treatment affordability

    Complete can help your commercial patients save: 

    • With the Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per month.
    • Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established.

    Empowering Patients
    Nurse Ambassadors, In Their Own Words

    Have questions or need support over the phone?

    Call 1-877-COMPLETE (1‑800‑274‑6867)

    *Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

    RINVOQ Complete: Terms and Conditions apply. This benefit covers RINVOQ® (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria. Co‑pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the RINVOQ Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

    HUMIRA Complete: Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

    Arava® and Plaquenil® are registered trademarks of their respective owners.

    Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

    How to enroll patients in
    RINVOQ complete

    Help patients get the support they need to start and stay
    on track with their prescribed treatment

    To enroll a patient in RINVOQ Complete:

    1

    Download the enrollment & prescription form for your specialty

    2

    Fill out the form with your patient

    • This form enrolls your patient and can be used to initiate a prescription with your patient's preferred specialty pharmacy.
    • The RINVOQ Complete Prescription section may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*
    3

    Fax the form to 1-678-727-0690

    • You will receive a call from an Access Specialist to discuss next steps.
    • If using the Pharmacy Prescription section, fax a copy to your patient's specialty pharmacy as well.
    4

    Inform your patient that they have been enrolled

    • Let your patient know to expect a call from their Nurse Ambassador.

    *Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

    Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

    Complete app

    COMPLETE APP

    Track treatment

    The Complete App helps patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:

    • Access additional resources, including a savings card for those that are eligible
    • Set customized medication reminders
    • Log and share symptoms with HCPs
    • Log medication lot number and medication expiration date
    Download on the App Store
    Get it on Google Play

    COMPLETEPRO.COM

    Streamline the Rx process

    CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.

     

    With CompletePro.com, you can:

    • Request benefits verifications
    • Complete and submit prior authorizations
    • Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
    • Receive alerts for annual reauthorizations and renewals
    • Track and monitor where patients are in the prescription process

    Learn more about streamlining the prescription process with Complete Pro:

    DOWNLOADABLE RESOURCES

    Download RINVOQ resources to support
    your patients and your practice.

    RINVOQ SAFETY DATA

    Review the well-studied safety profile of RINVOQ,
    including both short- and long-term analyses